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A combination of spectroscopic techniques, hydrogen/
deuterium exchange, and limited proteolysis experi-
ments coupled to mass spectrometry analysis was used
to depict the topology of the monomeric M* partly folded
intermediate of aspartate aminotransferase from Esch-
erichia coli in wild type (WT) as well as in a mutant form
in which the highly conserved cis-proline at position 138
was replaced by a trans-alanine (P138A). Fluorescence
analysis indicates that, although M* is an off-pathway
intermediate in the folding of WT aspartate aminotrans-
ferase from E. coli, it seems to coincide with an on-
pathway folding intermediate for the P138A mutant.
Spectroscopic data, hydrogen/deuterium exchange, and
limited proteolysis experiments demonstrated the oc-
currence of conformational differences between the two
M* intermediates, with P138A-M* being conceivably
more compact than WT-M*. Limited proteolysis data
suggested that these conformational differences might
be related to a different relative orientation of the small
and large domains of the protein induced by the pres-
ence of the cis-proline residue at position 138. These
differences between the two M* species indicated that in
WT-M* Pro138 is in the cis conformation at this stage of
the folding process. Moreover, hydrogen/deuterium ex-
change results showed the occurrence of few differences
in the native N2 forms of WT and P138A, the spectro-
scopic features and crystallographic structures of
which are almost superimposable.
The mechanism by which proteins fold into their unique
native structures is still a central problem in structural biology.
It is increasingly recognized that the structure of non-native
states of proteins can provide significant insight into funda-
mental issues such as the relationship between protein se-
quences and three-dimensional structures, the nature of pro-
tein folding pathways, the stability of proteins and their
turnover in the cell, and the transport of proteins across mem-
branes (1). Moreover, intermediate states experienced by pro-
teins in vivo often play a major role in protein association and
aggregation, leading to the “so-called” conformational diseases
(2). In contrast to the large amount of structural information
available on native folded proteins, however, too few partly
folded intermediates have been characterized thoroughly
enough to propose general models on how the native state is
attained and which is the structure of transient folding states.
Investigation of a wide range of non-native states would then
be of considerable value. To meet this need, new analytical
strategies able to characterize transient species and to define
the molecular details through which diverse proteins fold are
required.
Recently, structural biologists have turned their attention to
integrated strategies for the definition of the surface topology
of proteins and protein complexes. Although these approaches
provide low resolution data, they are amenable to the analysis
of transient species and partly folded intermediates. Limited
proteolysis and amide hydrogen exchange experiments in com-
bination with mass spectrometry have been employed to inves-
tigate the surface topology and the conformational flexibility of
proteins and protein complexes. Amide protons are exchanged
with deuterium with kinetics mainly depending on both solvent
accessibility and stabilization of the associated protein back-
bone region (3–5). Comparative hydrogen/deuterium exchange
(H/D)1 measurements can then be used to monitor protein
structural changes in different experimental conditions (6), as
well as the effects of binding or aggregation (7). Although
hydrogen exchange has most often been measured by NMR,
monitoring by mass spectrometry (MS) has become increas-
ingly common (8–13). As deuterium atoms replace protons
during the hydrogen exchange reaction, the mass of the protein
increases. The extent as well as the rate of exchange can then
be determined by measuring the increase in protein mass.
Proteolytic cleavages on a protein substrate can occur only if
the polypeptide chain is exposed and flexible enough to adapt to
the specific protease active site. The stable conformation of
proteins then provides some stereochemical barriers to enzy-
matic attack, leaving the exposed and flexible regions accessi-
ble to proteases and preventing the occurrence of proteolytic
cleavages within the highly structured core of the molecule.
Consequently, when these experiments are performed using a
series of proteases with different specificity under conditions
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that favors a single bond cleavage (complementary proteolysis),
the pattern of preferred cleavage sites will depict the exposed
regions in the protein molecule (14, 15). This strategy was also
employed to investigate conformational changes occurring in
protein structure under different experimental conditions (16–
19) or during quaternary forms interchange (20, 21), as well as
for the definition of the interface regions in protein complexes
(22–24).
This paper reports the application of these integrated strat-
egies to the structural characterization of partly folded inter-
mediates of wild type and a mutant form of Escherichia coli
aspartate aminotransferase (EcAspAT), in which the highly
conserved cis-proline in position 138 had been replaced by a
trans-alanine (P138A; Ref. 25). EcAspAT is a homodimer with
two identical and independent active sites located at the sub-
unit interface. Each subunit consists of an N-terminal arm, a
large cofactor-binding domain, and a small domain (26). Pro-
138 is located in a loop region of the large domain close to the
interface with the small domain (27). The replacement of a
cis-proline by a trans-alanine did not significantly affect either
the activity or the stability of the protein, as the catalytic
efficiency of P138A is of the same order of magnitude of WT,
and the thermal unfolding curves of the mutant and the WT are
almost superimposable (25). Additionally, the GdmHCl-in-
duced unfolding equilibrium of P138A mutant follows the same
pathway as the wild type protein (25). Nevertheless, the mu-
tant enzyme shows interesting folding features, because, de-
spite the replacement of a cis peptide bond with a trans one, the
refolding process is slower than wild type (25). Moreover, the
monomeric P138A-M* intermediate (25) detectable in the
GdmHCl-induced unfolding at equilibrium exhibited different
spectroscopic properties as compared with the wild type M*
species and resembles a kinetic folding intermediate.
EXPERIMENTAL PROCEDURES
Materials—Recombinant wild type and P138A mutant EcAspATs
were isolated from the overproducing E. coli strain TY103 (28) as
described previously (25). The proteins were stored at 80 °C in the
presence of 1 mM DTT and an excess of PMP and 2-oxoglutarate.
All experiments were carried out on the PLP form of the enzymes,
obtained by removal of excess PMP and 2-oxoglutarate either by exten-
sive dialysis against appropriate buffer or by gel filtration on a Super-
ose 12 PC column (3.2  30 mm) using the SMART system (Amersham
Biosciences). Subunit concentration of EcAspATs was determined spec-
trophotometrically on a Beckmann DU7500 spectrophotometer, using
280  49,935 M
1 cm1 (29).
L-1-Tosylamido-2-phenylethyl chloromethyl ketone-treated trypsin,
chymotrypsin, and subtilisin were purchased from Sigma; endoprotease
Lys C was from Roche Molecular Biochemicals. Reverse phase-HPLC
C4 columns (25  0.46 cm, 5 mm) were purchased from Vydac (The
Separation Groups). All other reagents and solvents were HPLC-grade
from Carlo Erba.
Spectroscopic Analysis—Native EcAspAT holoenzymes (in 10 mM
HEPES, pH 7.5, 1 mM DTT, and 0.15 M NaCl) were incubated at 25 °C
at the required protein and GdmHCl concentrations for 1 h (folding/
unfolding equilibrium was attained within 30 min, as determined in
preliminary experiments by following with time the enzymatic activity
and fluorescence), and protein solutions were filtered just before the
analysis on 0.22-m pore size polyvinylidene difluoride membrane
(Millipore).
Far-UV CD spectra were recorded on a Jasco J715 spectropolarime-
ter equipped with a Peltier thermostatic cell holder (Jasco model PTC-
348), in a quartz cell (0.1-cm light path) at a protein concentration of 1.0
M. Temperature was measured directly in the quartz cell, the solutions
were filtered just before use on 0.22-m pore size polyvinylidene diflu-
oride membrane (Millipore), and data corrected by subtracting a control
from which the protein was omitted. Spectra were recorded at 25 °C
from 280 to 200 nm at 0.2-nm resolution, 16-s response, at a scan rate
of 20 nm/min. All data are the averages of three measures, and the
results are expressed as mean residue ellipticity [], which is defined as
[]  100 obs/lc, where obs is the observed ellipticity in degrees, c is the
concentration in residue moles/liter, and l is the length of the light path
in centimeters.
Fluorescence measurements were carried out on a PerkinElmer
LB50S fluorimeter, using an optical cuvette of 10-mm light path length
with thermostatically controlled cell holder. Tryptophan emission spec-
tra were obtained at a protein concentration of 1.0 M using an excita-
tion wavelength of 295 nm, with excitation and emission bandwidths of
10 and 2.5 nm, respectively. Tryptophan emission spectra were re-
corded between 310 and 480 nm at a scan rate of 100 nm/min. Each
spectrum is the average of three emission scans, and data were cor-
rected by subtracting a blank from which the enzyme was omitted. ANS
fluorescence emission spectra were recorded on samples that had been
incubated at determined GdmHCl concentration for 30 min at 25 °C at
a protein concentration of 1.0 M before adding ANS to a final concen-
tration of 100 M. ANS emission spectra were recorded using an exci-
tation wavelength of 375 nm with excitation and emission bandwidths
of 5 and 5 nm, respectively between 400 and 600 nm at a scan rate of
100 nm/min. Each spectrum is the average of three emission scans, and
data were corrected by blank subtraction.
Single-jump refolding experiments were carried out by concentration
jumps of GdmHCl at 5 °C by rapid dilution of protein previously incu-
bated at required higher denaturant concentrations to the desired one
at a final protein concentrations of 0.39 M, and the subsequent time-
dependent changes in tryptophan or ANS fluorescence intensity were
monitored, under continuos stirring, at 333 or 475 nm, respectively.
Tryptophan Fluorescence Quenching—Fluorescence quenching titra-
tions with either acrylamide or iodide were performed at 25 °C by
sequential addition of aliquots of concentrated acrylamide (8 M) or
potassium iodide (5.34 M) stock solution into the protein solution. For
the native state, protein concentration was 3.9 M in 10 mM Na-HEPES,
pH 7.5, 1 mM DTT, 0.15 M NaCl in a range of acrylamide concentration
from 0 to 1.03 M. For the M* intermediate, iodide was added to the
protein (0.39 M previously incubated at 25 °C for 30 min in 10 mM
HEPES, pH 7.5, 1 mM DTT, and 0.15 M NaCl at 1.3 M GdmHCl for
P138A-M*, and 1.5 M GdmHCl for WT-M*) to obtain final iodide con-
centration ranging from 0 to 0.2 M. Fluorescence was measured at 25 °C
at the wavelength of the maximum in the fluorescence spectrum re-
corded in the absence of the quenching agent. Excitation was at 295 nm
(10-nm excitation bandwidth, 2.5-nm emission bandwidth), corrected
for the minor dilution caused by addition of the quenching agent and for
the background fluorescence of both solvent and quenching agent. Cor-
rection for the inner filter effect that resulted from the absorption of
acrylamide at 295 nm was applied by multiplying the fluorescence
intensity by 10A/2, where A is the absorbance of the solution at 295 nm
measured in a 1-cm path length cuvette. In the iodide experiments, 0.1
mM Na2S2O3 was included to prevent I
3 ion formation.
The fluorescence-quenching data in the presence of iodide quenching
data were analyzed according to the Stern-Vollmer equation (Equation
1) (30).
Fo/F 1KQ Q (Eq. 1)
Fo and F are the fluorescence intensities in the absence and presence of
quencher, respectively. KQ is the Stern-Vollmer quenching constant,
and [Q] is the concentration of the quencher. The plot of Fo/F versus [Q]
is linear for an apparently homogeneous population of emitting fluoro-
phores. Alternatively, a Stern-Vollmer-derived equation (Equation 2)
was used to calculate the fraction of accessible fluorescence, that is the
fraction of tryptophans that are exposed and then accessible to the
quenching agent.
Fo/Fo  F 1/QfaKQ 1/fa (Eq. 2)
fa is the fraction of accessible fluorescence.
The fluorescence-quenching data in the presence of acrylamide were
analyzed according to the Stern-Vollmer equation (Equation 3), modi-
fied to take into account a static contribution to quenching (31).
Fo/F 1KQQ])expVQ (Eq. 3)
V is the static constant.
Gel Filtration—Gel filtration experiments were carried out as fol-
lows. 50 l of the samples, 10 M in 10 mM HEPES, pH 7.5, 1 mM DTT,
and 0.15 M NaCl, equilibrated for 30 min at different concentrations of
GdmHCl, were loaded on a Superose 12 PC (3.2  300 mm) gel filtration
column installed on the Smart System (Amersham Biosciences), and
isocratically eluted in 10 mM HEPES, pH 7.5, 1 mM DTT, and 0.15 M
NaCl at the same concentration of GdmHCl used in the equilibration.
All experiments were carried out at 25 °C at a flow rate of 40 l/min.
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The column was calibrated in 10 mM HEPES, pH 7.5, 1 mM DTT, and
0.15 M NaCl in the absence of GdmHCl with the following proteins of
known molecular mass: -amylase (200,000 Da), cAspATp (92,000 Da),
bovine hemoglobin (67,000 Da), cytochrome c (12,300 Da).
Hydrogen/Deuterium Exchange—The H/D reaction was conducted as
follows; proteins were dissolved in 50 mM HEPES, pH 7.5, 1 mM DTT,
and 0.15 M NaCl at 25 °C, in the presence of 1.4 M GdmHCl in the case
of the two M* species, at a 8 M protein concentration, and allowed to
equilibrate for 30 min. Deuterium exchange reactions were initiated by
10-fold dilution of the sample with 50 mM HEPES, pH 7.5, D2O (con-
taining 1.4 M GdmHCl in the case of the two M* species). The exchange
reaction was allowed to proceed for lengths of time ranging from 30 to
60 min, and, at each time point, 1 nmol of protein was removed from the
labeling solution and rapidly injected into a 30 mm  0.46 mm (inner
diameter) perfusion column (POROS 10 R2 media, Applied Biosystems)
on an HPLC equipped with two Series 200 LC isocratic pumps (Applied
Biosystems) coupled to an API-100 single quadrupole mass spectrome-
ter (Applied Biosystems). The protein was eluted at a flow rate of 1
ml/min with a gradient of 25–95% acetonitrile in 0.1% trifluoroacetic
acid in 1.0 min. The HPLC step was performed with cold protiated
solvents, thereby reducing the back-exchange kinetics and removing
deuterium from side chains and N/C termini that exchange much faster
than amide linkages (32). Therefore, the increase in molecular mass
provided a direct measurement of the deuteration at peptide amide
linkages. Data were acquired and elaborated using the Biomultiviewer
(Applied Biosystems) program. Non-deuterated and totally deuterated
samples were used as control. The fully deuterated samples were pre-
pared by incubation for 1 h at 25 °C in 50 mM HEPES, pH 7.5, 1 mM
DTT, 0.15 M NaCl, 5 M GdmHCl in D2O at 8 M protein concentration.
LC/MS analysis was performed as above.
Limited Proteolysis Experiments—Limited proteolysis experiments
were carried out by incubating P138A-M*, WT-M*, P138A-N2, and
WT-N2 with trypsin, chymotrypsin, subtilisin, and endoprotease Lys C
using enzyme to substrate ratios ranging from 1:1000 to 1:5 (w/w).
Enzymatic digestions were all performed in 50 mM HEPES, pH 7.5, 1
mM DTT, and 0.15 M NaCl at 25 °C, in the presence of the desired
concentration of GdmHCl (1.3 M for P138A-M*, 1.5 M for WT-M*), and
without GdmHCl for the two native forms), at a 1 M protein concen-
tration. In the case of P138A-M* and WT-M*, each protein was incu-
bated for 30 min in the reaction solution, before adding the selected
enzyme. The extent of the reactions was monitored on a time-course
basis by sampling the incubation mixture at different time intervals.
Proteolytic fragments were analyzed by LC/MS performed on an API
100 single quadrupole electrospray (Applied Biosystems) equipped with
two Series 200 LC isocratic pumps (Applied Biosystems). Chromato-
graphic separation was obtained on a C4 column by the means of a
40-min linear gradient from 20 to 70% of acetonitrile in 2% formic acid
and 0.1% trifluoroacetic acid. Mass spectra were acquired on a m/z
interval ranging from 600 to 1800. Data were elaborated using the
Biomultiviewer program, purchased from PE-Sciex. Mass calibration
was performed by means of multiply charged ions from a separate
injection of horse heart myoglobin (Sigma; average molecular mass:
16,951.5 Da); all masses are reported as average values.
RESULTS AND DISCUSSION
The M* Intermediate—Previous studies suggested that Gd-
mHCl-induced unfolding at equilibrium of EcAspAT at 20 °C is
reversible and proceeds through the formation of at least two
monomeric intermediates along the unfolding pathway (33).
N2º 2Mº 2Mº 2U
REACTION 1
N2 is the native dimer, M and M* are distinct “structured”
monomers, and U is the unfolded state. As described by Herold
and Kirschner (33), the first intermediate M, the folded mono-
mer of EcAspAT, is partially populated at 	0.6 M GdmHCl and
only at low protein concentrations. The second monomeric in-
termediate, M*, accumulates at 1 M GdmHCl and constitutes a
“molten globule”-like species, which retains part of the tertiary
and secondary structure of the native state.
The unfolding process of both WT EcAspAT and the P138A
mutant was investigated by fluorescence, gel filtration, and CD
analysis and the corresponding M* species, identified according
to the results reported by Herold and Kirschner (33) and to
size-exclusion chromatography data in GdmHCl at equilibrium
(34), were thoroughly characterized. Preliminary experiments
(25) showed that folding/unfolding equilibrium was attained
within 30 min and that, under the experimental conditions
used, the folding intermediates were stable. No precipitation of
protein was observed after incubation at the protein concentra-
tion used, and gel filtration analysis ruled out the presence of
soluble aggregates (see below).
Because the enzyme has five tryptophan residues located in
various regions of its three-dimensional structure, with one
positioned in the active site pocket, tryptophan fluorescence
was used as a probe for global changes in tertiary structure of
EcAspAT during protein unfolding and to distinguish between
M and M* (33). In our experimental conditions, i.e. relatively
high protein concentration (in the 1–10 M range) and the
presence of pyridoxal 5-phosphate, the N2 º 2M transition
escaped fluorescence detection. This transition, indeed, is
shifted toward higher denaturant concentrations by increasing
the protein concentration and by the presence of the cofactor
(33), thus overlapping with the M to M* transition.
Fig. 1 shows the bathochromic shift of the fluorescence max-
imum for WT EcAspAT and the mutant as the concentration of
GdmHCl increased. The unfolding process is clearly biphasic
for both proteins, and a stable intermediate state, correspond-
ing to the M* species, could be detected at given GdmHCl
concentrations. Therefore, the first fluorescence-detected tran-
sition observed included both the dissociation of the dimer and
the conversion to M*. Accordingly, the change in the fluores-
cence spectrum reflects both structural changes and the loss of
the coenzyme (PLP) during unfolding.
A clear difference in the emission spectra of the M* interme-
diates of the two proteins was observed. The fluorescence spec-
trum of the M* from P138A displayed a maximum at 337 nm,
red-shifted by 5 nm as compared with the wild type enzyme
(max at 342 nm). This change of the maximum wavelength is
significant because no variation greater than 
0.5 nm was
FIG. 1. GdmHCl-induced unfolding curves of EcAspAT. Figure
shows zoom of the transition occurring in the 0.5–1.5 M range of the
unfolding process of WT (f) and P138A (*), as monitored by the changes
in tryptophanyl emission maximum upon excitation at 295 nm. The
entire unfolding curve is reported in the inset.
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observed in several spectra recorded for each sample. On the
contrary, in the native and in the unfolded states, the emission
spectra of P138A and WT were nearly coincident.
Gel filtration analysis of EcAspAT carried out at different
GdmHCl concentrations (Fig. 2) showed that the elution vol-
ume of the enzyme increased to a broad maximum between 0.7
and 1.2 M GdmHCl and then gradually decreased at higher
denaturant concentrations, according to previous reports (33,
34). In all conditions, the protein eluted as a rather symmetric
peak, consistent with homogeneous species. Moreover, no dif-
ferences were detected in the elution volume of WT-M* and
P138A-M* at 1.4 M GdmHCl, indicating that no differences in
the compactness of the intermediates could be inferred by these
analyses. However, both M* forms showed an elution volume in
between that of the native N2 and that expected for the folded
monomer M, thus indicating that in these conditions the M*
species are monomeric and have a compact structure, albeit not
as structured as the folded monomeric protein. Therefore, all
the experiments described below were carried out at equal or
lower EcAspAT concentrations to ensure the monomeric state
of the protein.
The native, M*, and denatured states of the two proteins
were then analyzed by circular dichroism. Fig. 3 shows the CD
spectra of the three forms of P138A, which were coincident with
those recorded for the respective WT forms (data not shown). In
both cases, the M* species showed a CD signal at 222 nm that
is 58% of the native protein, indicating that these intermedi-
ates have a considerable amount of apparent secondary
structure.
Tryptophan Fluorescence Quenching—The native and M*
states of the two proteins were submitted to fluorescence
quenching experiments using acrylamide and iodide as quench-
ing agents. Fig. 4A shows the results of the acrylamide quench-
ing experiments on the native states, revealing that the fluo-
rescence behavior of P138A and WT are almost in-
distinguishable, as can be inferred from the KQ values reported
in Table I.
Acrylamide quenching experiments on the M* intermediates
were impaired by protein aggregation occurring even at low
acrylamide concentrations. In contrast, quenching experiments
with iodide could be carried out on the M* intermediates at
0.39 M protein concentration without major problems. The
results reported in Fig. 4B demonstrated that the tryptophan
residues responsible for the fluorescence of the M* intermedi-
ate are less exposed in P138A than in WT, as also shown by the
FIG. 3. CD analysis of P138A. The far-UV circular dichroism spec-
tra of P138A were recorded at 0, 1.4, and 5 M GdmHCl, where the native
(N2), M* intermediate, and unfolded (U) species predominate
respectively.
FIG. 4. Stern-Vollmer plots of the quenching of tryptophan
fluorescence of WT (f) and P138A () in the native state N2 (A)
and in the M* intermediate (B). A, quenching of the native state
fluorescence by acrylamide. Spectra were recorded at 25 °C at the
wavelength of the maximum of the native state in the absence of the
quencher, upon excitation at 295 nm. Data were fitted to Equation 3. B,
quenching of the M* intermediate. Proteins (0.39 M) were incubated at
1.5 M GdmHCl for WT (f) and 1.3 M GdmHCl for P138A (). Fluores-
cence was recorded at 25 °C at the wavelength of the maximum of the
M* intermediate in the absence of the quencher, upon excitation at 295
nm. Data were fitted to Equation 1.
FIG. 2. Gel filtration analysis of GdmHCl-induced unfolding of
EcAspAT. Figure shows change of elution volume of WT (f) and P138A
(*) as a function of GdmHCl concentration.
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KQ values reported in Table I. Iodide quenching data were
analyzed to define the number of tryptophan residues involved
in quenching. From the fa values calculated by Equation 2, 4.30
(
 0.30) of 5 total tryptophan residues could be quenched in the
M* intermediate of WT as compared with only 3.05 (
 0.25) in
P138A. The quenching data obtained for both WT and P138A in
the denatured state were interpolated with the same equation
as a control, giving an fa value of 1, thus indicating that all
tryptophans are exposed in the denatured form (data not
shown). Again these data suggested a different arrangement of
the three-dimensional structure in the M* intermediates from
WT and P138A.
Equilibrium and Kinetic Intermediates—Fig. 5A shows the
kinetic progress for the refolding of WT at 5 °C from fully
unfolded state (5 M GdmHCl) by 50-fold dilution into refolding
buffer (0.1 M K-HEPES, pH 7.5, 1 mM DTT), at a final protein
concentration of 0.39 M. A transient intermediate I1* accumu-
lated within 50 s and then slowly evolved to the native state in
a biphasic curve that can be fitted to a double exponential with
the kinetic constants reported in Table II. The folding events
leading to I1* escaped detection; however, using the extrinsic
probe for hydrophobic surfaces, ANS, the formation of a further
folding intermediate I2* within the dead time of manual mixing
was observed (Fig. 5B). It is worth mentioning that ANS does
not bind either the unfolded EcAspATs or the native proteins,
whereas the M* form of both WT and P138A interacts with
ANS, as shown by increased fluorescence intensity emission at
475 nm upon excitation at 375 nm of the extrinsic probe (data
not shown).
When the formation of M* was initiated by diluting the WT
protein from 5 M GdmHCl to 1.4 M GdmHCl and monitored by
tryptophanyl fluorescence (Fig. 5C), a constant signal was ob-
tained within the dead time of manual mixing. Following a
further GdmHCl dilution to the native state, the fluorescence
signal rapidly increased up to an intensity value similar to that
of the I1* detected in the refolding experiment described above
(see Fig. 5A) and then slowly decreased to the native value.
Therefore, in WT the equilibrium M* intermediate is clearly
distinct from the transient intermediate I1* that could still be
detected in the refolding pathway from M* to N2. When the
same experiment was carried out on P138A, a different behav-
ior was observed (Fig. 5D). Formation of M* from the unfolded
mutant occurred with a slower kinetic than in the WT, and the
M* intermediate was characterized by the same tryptophanyl
fluorescence intensity at 333 nm displayed by the I1* species.
Moreover, following dilution to the native state, no increase in
the fluorescence intensity was detected with the signal simply
decaying to the N2 value, indicating that no other intermediate
accumulated on the refolding pathway from M* to N2. There-
fore in P138A the spectroscopic features of the M* intermediate
are very similar to those of the I1* transient species, suggesting
that M* might be an on-pathway folding intermediate possibly
coincident with I1*.
These results confirmed the hypothesis that cis-prolines play
a subtle role in directing the traffic of intermediates toward the
unique structure of the native state, rather than to respond to
the needs for specific catalytic or functional roles (25). How-
ever, the involvement of trans-cis isomerization of the peptide
bond preceding Pro-138 is not as simple as hypothesized by
Leistler and colleagues (35), who indicated this event as one of
the possible rate-limiting steps leading to the two slow phases
observed in WT refolding. Addition of a peptidyl prolyl isomer-
ase, cyclophilin A, to the refolding solution did not alter either
the fluorescence decay or the activity recovery (data not
shown). Nevertheless, the ineffectiveness of cyclophilin A to
catalyze the two slow phases, does not rule out an involvement
of isomerization in the refolding of EcAspAT either at the early
stages of the process or when the trans peptide bond is already
buried in the protein and is then not accessible to the isomer-
ase. It should be noted that refolding of P138A from 5 M Gdm-
HCl still shows the presence of two slow phases with kinetic
constants similar to those calculated for WT (Table II), even in
the absence of any cis/trans isomerization at Ala-138.
Hydrogen/Deuterium Exchange—Isotopic exchange at pep-
tide bond protons basically depends on whether they are par-
ticipating in intramolecular hydrogen bonding and on the ex-
tent of solvent shield exerted by the protein structure.
Measurements of protein mass increase following hydrogen/
deuterium exchange may then be used as a sensitive probe to
monitor conformational changes in protein structure. A com-
parative characterization of N2 and M* species from WT and
P138A was carried out by hydrogen/deuterium exchange exper-
iments followed by ES/MS analysis. Protein solutions (20 M)
were 10-fold diluted by the addition of the appropriate D2O
buffers, and deuterium incorporation was monitored by sam-
pling the incubation mixture at different interval times fol-
lowed by cold acid quenching and fast LC/MS analysis.
Fig. 6A shows the number of amide protons exchanged with
deuterium in the native form of WT and P138A as a function of
time. Following 60 min of reaction, a total of 120 
 6 hydrogens
were replaced with deuterium atoms in both proteins. This
value corresponds to 	30% of the theoretically exchangeable
protons, thus confirming the high level of compact structure of
the native form of both proteins. However, a clear difference in
the exchange kinetics between the WT and the mutant was
detected. Incorporation of deuterium atoms occurred much
faster in P138A than in WT, suggesting a higher degree of
flexibility for the N2 state of the mutant.
The CD and fluorescence studies of the native state of the
two proteins reported above had yielded almost indistinguish-
able spectroscopic characteristics. Moreover, inspection of x-
ray data indicated that the crystallographic structures of
P138A and WT are superimposable but for a small region
surrounding the mutation site (25). Nevertheless, some differ-
ences in the conformation of the two proteins could be detected
by H/D exchange experiments. These differences should very
likely be related to the dynamics of the proteins and are then
not readily observed in static three-dimensional structures.
The faster kinetics of deuterium incorporation observed in
P138A could in fact be interpreted in terms of a wider protein
breathing experienced by the mutant with respect to WT. On
the other hand, the same extent of total proton exchange shown
by the two proteins confirms their nearly identical three-di-
mensional structure.
The exchange experiments on the M* species were performed
by incubation of the intermediates in deuterated buffer for 60
min followed by ES/MS analysis, from which a number of
considerations could be drawn. The single envelope of isotope
peaks occurring in the mass spectra (Fig. 6B) indicated a EX1
kinetics of hydrogen and deuterium exchange according to Bai
et al. (32), confirming that the M* species of both P138A and
WT are homogeneous and stable folding intermediates. The
isotope pattern distribution is an important source of informa-
tion on sample heterogeneity. For structurally heterogeneous
TABLE I
Parameters for the quenching of tryptophan fluorescence of wild-type
and P138A mutant aspartate aminotransferases
Protein KQ native state
a KQ M* state
b
WT 0.718 
 0.078 5.630 
 0.052
P138A 0.759 
 0.036 4.533 
 0.055
a KQ values were determined with Equation 3.
b KQ values were determined with Equation 1.
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samples, such as the mixture of folded and unfolded molecules,
or the presence of different aggregation states, multiple enve-
lope of isotope peaks are expected, each with different hydrogen
exchanging characteristics, whereas homogeneous samples
show a single envelope of isotope peaks at all incubation times.
As expected, a much higher extent of isotopic exchange was
observed for the M* species with respect to the native forms;
M* intermediates from P138A and WT incorporated 245 
 7.8
and 286 
 9 deuterium atoms corresponding to 61 and 71% of
the exchangeable protons, respectively. The large increase in
the number of exchanged protons might be ascribed both to the
dissociation of the dimeric native state of the proteins into the
monomeric forms and to the partial unfolding of the protein
structure leading to the M* state. Because 40% of the amide
protons in P138A and more than 32% in WT are still shielded
to the solvent in the M* form, these results confirm previous
spectroscopic data that the M* species are partly folded inter-
mediates still retaining a significant amount of secondary and
tertiary structure.
Finally, the M* from P138A exchanged significantly fewer
hydrogen atoms than the corresponding intermediate from WT,
	40 protons corresponding to nearly 16% of the total ex-
changed hydrogens. This result demonstrated that the M* in-
termediates from P138A and WT are different, confirming the
spectroscopic data reported above, with the M* species from
P138A exhibiting a more compact and less flexible structure.
Limited Proteolysis of M* Intermediates from P138A and
WT—The surface topology of the M* intermediates from P138A
and WT was investigated by a strategy that combines limited
proteolytic digestions with mass spectrometric identification of
the released fragments. Limited proteolysis experiments were
performed using trypsin, chymotrypsin, endoprotease Lys C,
and subtilisin as proteolytic probes under conditions in which
the M* intermediates were monomeric and exhibited maximal
stability. The M* species were incubated with each protease
using an appropriate enzyme to substrate ratio, and the extent
of the enzymatic hydrolysis was monitored on a time-course
basis by sampling the incubation mixture at different interval
times followed by LC/MS analysis. The chromatographic and
mass spectrometric identification of the fragments released
from the protein led to the assignment of preferential cleavage
sites.
protein concentration of 19.5 M, then rapidly diluted at 5 °C (final
protein concentration 0.39 M, final GdmHCl concentration 0.1 M), and
tryptophanyl (A) and ANS (B) fluorescence recorded. The fluorescence
value of the unfolded protein is also reported in the figures as reference
starting point. C and D, step refolding of WT (C) and P138A (D) from U
to M* (a) and from M* to N2 (b). All the experiments were carried out at
a protein concentration of 0.39 M in the presence of the required
concentration of GdmHCl. C, a, WT was incubated at 25 °C for 30 min
in 5 M GdmHCl, after which refolding to M* was initiated by rapidly
diluting at 5 °C to 1.5 M GdmHCl; b, WT was incubated at 25 °C for 30
min in 1.5 M GdmHCl, after which refolding to N2 was initiated by
rapidly diluting at 5 °C to 0.1 M GdmHCl. D, a, P138A was incubated at
25 °C for 30 min in 5 M GdmHCl, after which refolding to M* was
initiated by rapidly diluting at 5 °C to 1.3 M GdmHCl; b, P138A was
incubated at 25 °C for 30 min in 1.3 M GdmHCl, after which refolding to
N2 was initiated by rapidly diluting at 5 °C to 0.1 M GdmHCl.
FIG. 5. Refolding of EcAspAT followed by fluorescence. A and
B, WT protein was incubated at 25 °C for 30 min in 5 M GdmHCl at a
TABLE II
Kinetic constants calculated for the two slow phases of refolding of
WT and P138A from intrinsic fluorescence intensity decay
Kinetic constants were calculated by fitting the decreasing part of the
refolding curve (such as in Fig. 5A) to a double exponential.
k1 k2
s1 s1
WT 2.139  103 
 6.4  105 5.05  104 
 1.3  105
P138A 1.880  103 
 6.4  106 1.95  104 
 6.8  106
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FIG. 6. Hydrogen/deuterium ex-
change in EcAspAT monitored by ES/
MS. A, the number of exchanged protons
in WT-N2 (f) and P138A-N2 () was cal-
culated by the increase in the molecular
mass of the two proteins and is reported
as a function of the exchange time. B,
electrospray m/z signals of the 40 and
34 ions of P138A-M* (a) and WT-M* (b)
after 60 min of incubation in buffered
D2O.
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As an example, Fig. 7 shows the LC/MS chromatograms of
the aliquots withdrawn following 30, 60, and 90 min of chymo-
tryptic digestion of M* from P138A, performed using an en-
zyme to substrate ratio of 1:500 (w/w). After 30 min of hydrol-
ysis, four major peaks appeared (fractions 1–4 in Fig. 7), the
intensity of which increased at later stages of incubation. Mass
spectrometric analysis of these fractions identified the two
complementary pairs 1–59/60–411 (peaks 1 and 3 in Fig. 7) and
1–380/381–411 (peaks 2 and 3), and the undigested protein
(peak 4). These data clearly indicated Tyr-59 and Tyr-380 as
preferential chymotryptic cleavage sites, suggesting that these
residues are located in a flexible and exposed region of the M*
structure.
The overall data from the complementary proteolysis exper-
iments are summarized in Table III and Fig. 8. A small number
of preferential cleavage sites was observed in both M* species,
indicating the occurrence of a rather structured conformation
exhibiting low accessibility to proteases. In combination with
spectroscopic and H/D exchange data, these results demon-
strate that the two M* intermediates possess a stable and well
defined three-dimensional structure that prevent the occur-
rence of a diffuse and random distribution of proteolytic cleav-
ages. Moreover, very few cleavages were observed at residues
that in the native structure are located within the subunit
interfaces, indicating that the exposure of M* regions was not
merely the result of dissociation of the dimeric structure. Fi-
nally, proteolytic sites were identified both in the small and in
the large domain of the protein, thus excluding the possibility
that M* originated from the unfolding of only one of the two
domains.
The preferential cleavage sites observed in M* from P138A
essentially gathered into two separate regions of the protein,
i.e. the segments 98–121 and 266–288, whereas few isolated
sites were detected at Tyr-59, Ser-136, Ala-150, and Tyr-380. It
should be noted that no cleavage was detected in the N-termi-
nal arm that in the dimeric form of EcAspAT embraces the
partner subunit concurring in the formation of the active site.
This observation suggests that, following dissociation of N2 into
M, the monomeric form should undergo conformational
changes to generate the M* species in which the N-terminal
tail is forced to interact with the protein body and is then
protected from the proteases. Otherwise, the flexible N-termi-
nal arm would have been cleaved by proteases at several sites.
A greater number of cleavage sites and a faster kinetic of
hydrolysis was observed in all the experiments on the M*
species from WT, confirming that the two intermediates exhibit
a different three-dimensional arrangement with the conforma-
tion of M* from WT being generally more flexible and less
structured than P138A-M*. These results are in excellent
agreement with previous H/D exchange experiments depicting
a higher flexibility of the WT-M* species that showed a larger
extent of deuterium incorporation.
Accordingly, besides the exposed regions already observed in
P138A-M*, additional proteolytic sites in WT-M* were identi-
fied within the segments 20–25 and 39–41 with few isolated
cleavages observed at Tyr-59, Tyr-161, and Phe-188. Particu-
larly, the region 39–41 and Tyr-161 are located at the inter-
domain interface. Occurrence of proteolytic cleavages at this
region only in WT-M* suggests that the structural differences
between the two M* intermediates might be ascribed to a
different relative orientation of the two domains. The relative
rotation of the two domains might also affect the conformation
of the N-terminal tail, thus explaining the accessibility of the
segment 20–25, located in the small domain close to the N
terminus of the protein.
Comparative proteolysis experiments were also performed
on the native dimeric forms of P138A and WT, using the same
conditions employed for the M* intermediates. Both proteins
were completely resistant to proteases, and no cleavage was
detected at any time of incubation even when the E/S ratio was
increased up to 50-fold.
Conclusion—A combination of spectroscopic techniques, H/D
exchange, and limited proteolysis experiments coupled to mass
spectrometry analysis were used to depict the topology of the
M* partly folded intermediate of EcAspAT in WT as well as in
the mutant protein P138A.
The role of intermediates in the protein folding is a contro-
versial issue. In some cases, they appear to be important mile-
stones for productive folding (i.e. they are on-pathway),
whereas, in other cases, they might arise by nonspecific col-
lapse of the polypeptide chain or accumulate because they are
trapped by non-native interactions (i.e. they are off-pathway).
M* is an off-pathway intermediate in the folding process of WT
EcAspAT, as already pointed out by Leistler et al. (35), whereas
spectroscopic data provided in this study suggest that the M*
species from the mutant P138A is coincident with the on-
pathway folding intermediate I1*.
Gel filtration and CD analysis did not show major differences
between the two M* species. On the contrary, the increased
deuterium incorporation level and the higher accessibility to
proteases shown by WT-M* as compared with P138A-M* dem-
onstrated the occurrence of conformational differences between
the M* intermediates. These results together with fluorescence
data indicate that P138A-M* is conceivably more compact than
WT-M*.
In particular, limited proteolysis results suggested that
FIG. 7. Time-course analysis of P138A-M* digested with chy-
motrypsin under controlled conditions. Figure shows HPLC pro-
files of the aliquots withdrawn from the incubation mixture at 30 min
(A), 60 min (B), and 90 min (C). Individual fractions were identified by
ES/MS.
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these conformational differences might be related to a different
relative orientation of the small and large domains. These data
can be compared with those reported by Martinez-Carrion and
co-workers (36, 37) during the early stages of refolding of mi-
tochondrial AAT (mAspAT) that shares 42% identity with
EcAspAT. Although mAspAT does not show stable folding in-
termediates, the pattern of preferential proteolytic sites in the
N-terminal region are in good agreement with that obtained on
WT-M*. Because cis-Pro-138 is conserved in mAspAT, this
common behavior might indicate that isomerization of the 137–
138 peptide bond during the folding process affects the relative
rotation of the two domains causing the exposition of the N-
terminal region. These conformational changes do not occur in
the P138A mutant, where the 137–138 peptide bond is in the
trans configuration, originating a more compact structure and
preventing proteolysis in the N-terminal region.
In the light of the conformational differences between the
two M* species, it is clear that the peptide bond preceding
Pro-138 in WT-M* is in cis conformation at this stage of the
folding process. A direct link between cis-trans isomerization at
position 138 and folding of EcAspAT cannot be easily depicted
(25). This event certainly plays some role, as demonstrated by
the different characteristics of the two M*, and, even more, by
the slower reactivation of P138A (25). However, other rear-
rangements related to the cis-trans isomerization may rule the
folding process of this protein. For instance, some favorable
tertiary interactions in key folding intermediates might be
formed only following cis-trans isomerization at position 138,
thus leading to a slower reactivation in P138A rather than in
WT, or, alternatively, isomerization at position 138 occurring
at the early stages of refolding, might direct the process into a
different route.
Finally, it is intriguing to observe that the H/D exchange
results showed few differences in the native N2 forms of WT
TABLE III
Preferential cleavage sites detected on the P138A-M* and WT-M* intermediates in the different limited proteolysis experiments
Differently exposed residues are highlighted in bold type.
P138A-M* WT-M*
Trypsin Arg-101, Arg-266 Arg-25, Arg-101, Arg-266
Chymotrypsin Tyr-59, Tyr-380 Phe-24, Tyr-40, Tyr-59, Tyr-161, Phe-188, Tyr-256, Tyr-380
Lys C Lys-98, Lys-121, Lys-288 Lys-41, Lys-98, Lys-121, Lys-288
Subtilisin Ala-115, Ser-136, Ala-150, Cys-270, Tyr-380 Leu-20, Val-39, Phe-188, Cys-270, Tyr-380
FIG. 8. Map of cleavage sites on EcAspAT. Preferential proteolytic sites are mapped onto the amino acid sequence of EcAspAT. Cleavage sites
only occurring in WT-M* are indicated by dashed arrows, those only present in P138A-M* by empty arrows, and those observed in both proteins
by filled arrows. Dotted, underlined, and double underlined regions indicate N-terminal tail, the large domain, and the small domain, respectively.
Residues occurring at the domain interface are highlighted in gray. Amino acid numbering is based on the sequence of porcine cytosolic aspartate
aminotransferase (38).
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and P138A, the spectroscopic features and crystallographic
structures of which are almost superimposable. Flipping of the
137–138 peptide bond from the cis conformation of WT to the
trans conformation of P138A resulted in an overall increased
“motility” of the fraction of the protein that is accessible to the
solvent in the native form.
Limited proteolysis and H/D exchange experiments in con-
junction with mass spectrometry analysis well complemented
spectroscopic results, thus providing a wealth of data that
allowed a detailed structural analysis of EcAspAT folding in-
termediates. On a more general ground, these results suggest
that the integration of spectroscopic investigations and mass
spectrometric procedures might be instrumental in providing
subtle structural details on transient conformations such as
those present along a folding pathway.
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